Market revenue in 2023 | USD 3,730.7 million |
Market revenue in 2030 | USD 11,135.3 million |
Growth rate | 16.9% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 80.57% in 2023. Horizon Databook has segmented the Germany precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Germany's precision medicine market is expected to grow at a lucrative rate over the forecast period. This can be attributed to the ongoing advancements in personalized medicine in Germany by public and private organizations, such as EuroBioForum, the German Center for Infection Research, and the Personalized Medicine Coalition (PMC).
Local advancement programs and approaches such as the Munich Biotech Cluster m4 approach for personalized medicine; Greifswald Approach to Individualized Medicine (GANI_MED), “Individualized Medicine: a New Way in Research and Healthcare” plan by the Federal Ministry of Education and Research; the Helmholtz Cross-Program Initiative Personalized Medicine iMed by Helmholtz Association are some of the notable efforts undertaken in the region.
The German Federal Ministry of Health launched the genomeDE National Strategy for Genomic Medicine in February 2019. One of the goals of this initiative was to develop the infrastructure of genomics in the country to promote the use of personalized medicine.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Germany precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account